{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban", "query": { "intervention": "Edoxaban" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T17:44:37.327Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02073682", "title": "Cancer Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Cancer" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Low molecular weight heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1046, "start_date": "2015-07-16", "completion_date": "2017-09-15", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 4, "location_summary": "Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Jonesboro", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073682" }, { "nct_id": "NCT00781391", "title": "Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stroke", "Atrial Fibrillation", "Embolism" ], "interventions": [ { "name": "warfarin tablets", "type": "DRUG" }, { "name": "Edoxaban tablets (high dose regimen-60mg)", "type": "DRUG" }, { "name": "Edoxaban tablets (low dose regimen-30mg)", "type": "DRUG" }, { "name": "placebo warfarin", "type": "DRUG" }, { "name": "placebo edoxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 21105, "start_date": "2008-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 316, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00781391" }, { "nct_id": "NCT02303431", "title": "Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Deep Vein Thrombosis", "Venous Thromboembolism" ], "interventions": [ { "name": "Edoxaban low dose", "type": "DRUG" }, { "name": "Edoxaban high dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 66, "start_date": "2014-11-05", "completion_date": "2021-09-16", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02303431" }, { "nct_id": "NCT03271450", "title": "The DARE Warfarin CER Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Deep Venous Thrombosis", "Pulmonary Embolism" ], "interventions": [ { "name": "Dabigatran: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Dabigatran: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Apixaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Rivaroxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Edoxaban: extended treatment (e.g at least 270 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 90 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 180 days)", "type": "DRUG" }, { "name": "Warfarin: extended treatment (e.g at least 270 days)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416000, "start_date": "2017-07-01", "completion_date": "2021-10-30", "has_results": false, "last_update_posted_date": "2021-06-23", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271450" }, { "nct_id": "NCT02798471", "title": "Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Pulmonary Embolism", "Deep Vein Thrombosis (DVT)" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 290, "start_date": "2017-03-27", "completion_date": "2022-05-24", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798471" }, { "nct_id": "NCT02072434", "title": "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2199, "start_date": "2014-03-25", "completion_date": "2016-02-03", "has_results": true, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072434" }, { "nct_id": "NCT02744092", "title": "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Venous Thromboembolism", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Blood Clot" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dabigatran", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Fondaparinux", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 811, "start_date": "2016-12-13", "completion_date": "2021-02-22", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 151, "location_summary": "Chula Vista, California • Fremont, California • Fresno, California + 104 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02744092" }, { "nct_id": "NCT03310021", "title": "A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Andexanet alfa", "type": "BIOLOGICAL" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Portola Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 108, "start_date": "2017-08-28", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310021" }, { "nct_id": "NCT02207257", "title": "Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anticoagulation Reversal" ], "interventions": [ { "name": "PER977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Edoxaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2014-03", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02207257" }, { "nct_id": "NCT01662908", "title": "A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Deep Vein Thrombosis", "Venous Thrombosis" ], "interventions": [ { "name": "edoxaban tosylate", "type": "DRUG" }, { "name": "enoxaparin/unfractionated heparin", "type": "DRUG" }, { "name": "warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2012-08", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-01T17:44:37.327Z", "location_count": 29, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Sacramento, California + 26 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662908" } ] }